AChRα10 Polyclonal Antibody

    • Catalog No.:YT0081
    • Applications:WB;ELISA
    • Reactivity:Human;Mouse;Rat
      • Target:
      • AChRα10
      • Fields:
      • >>Neuroactive ligand-receptor interaction
      • Gene Name:
      • CHRNA10
      • Protein Name:
      • Neuronal acetylcholine receptor subunit alpha-10
      • Human Swiss Prot No:
      • Q9GZZ6
      • Immunogen:
      • The antiserum was produced against synthesized peptide derived from human CHRNA10. AA range:394-443
      • Specificity:
      • AChRα10 Polyclonal Antibody detects endogenous levels of AChRα10 protein.
      • Formulation:
      • Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
      • Source:
      • Polyclonal, Rabbit,IgG
      • Dilution:
      • WB 1:500 - 1:2000. ELISA: 1:20000. Not yet tested in other applications.
      • Purification:
      • The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
      • Concentration:
      • 1 mg/ml
      • Storage Stability:
      • -15°C to -25°C/1 year(Do not lower than -25°C)
      • Other Name:
      • CHRNA10;NACHRA10;Neuronal acetylcholine receptor subunit alpha-10;Nicotinic acetylcholine receptor subunit alpha-10;NACHR alpha-10
      • Observed Band(KD):
      • 50kD
      • Background:
      • function:Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.,miscellaneous:The hetero-oligomeric receptor composed of CHRNA9 and CHRNA10 has an atypical pharmacological profile, binding several non-nicotinic ligands including strychnine (a glycine receptor antagonist) and atropine (a muscarinic acetylcholine receptor antagonist).,similarity:Belongs to the ligand-gated ionic channel (TC 1.A.9) family.,subunit:Forms hetero-oligomeric channels in conjunction with CHRNA9. The native outer hair cell receptor may be composed of CHRNA9-CHRNA10 hetero-oligomers.,tissue specificity:Expressed in inner-ear tissue, tonsil, immortalized B-cells, cultured T-cells and peripheral blood lymphocytes.,
      • Function:
      • function:Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma.,miscellaneous:The hetero-oligomeric receptor composed of CHRNA9 and CHRNA10 has an atypical pharmacological profile, binding several non-nicotinic ligands including strychnine (a glycine receptor antagonist) and atropine (a muscarinic acetylcholine receptor antagonist).,simi
      • Subcellular Location:
      • Cell junction, synapse, postsynaptic cell membrane ; Multi-pass membrane protein . Cell membrane ; Multi-pass membrane protein .
      • Expression:
      • Expressed in inner-ear tissue, tonsil, immortalized B-cells, cultured T-cells and peripheral blood lymphocytes.
      • Products Images
      • Western Blot analysis of various cells using AChRα10 Polyclonal Antibody
      • Western Blot analysis of A549 cells using AChRα10 Polyclonal Antibody
      • Western blot analysis of lysates from HeLa, 293, COLO, and A549 cells, using CHRNA10 Antibody. The lane on the right is blocked with the synthesized peptide.